MX2022001942A - Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas. - Google Patents
Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas.Info
- Publication number
- MX2022001942A MX2022001942A MX2022001942A MX2022001942A MX2022001942A MX 2022001942 A MX2022001942 A MX 2022001942A MX 2022001942 A MX2022001942 A MX 2022001942A MX 2022001942 A MX2022001942 A MX 2022001942A MX 2022001942 A MX2022001942 A MX 2022001942A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen
- binding molecules
- multispecific antigen
- cell targeting
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona moléculas multiespecíficas de unión a antígenos que se unen tanto a un antígeno de un linfocito T (p. ej., CD3) como a un antígeno diana (p. ej., un antígeno tumoral o un antígeno viral o bacteriano) y que incluyen una única cadena polipeptídica multivalente (p. ej., bivalente) en cuanto a la unión a antígenos de linfocitos T, así como usos de estas moléculas.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962887411P | 2019-08-15 | 2019-08-15 | |
US201962924435P | 2019-10-22 | 2019-10-22 | |
US202062978584P | 2020-02-19 | 2020-02-19 | |
US202063057824P | 2020-07-28 | 2020-07-28 | |
PCT/US2020/046352 WO2021030680A1 (en) | 2019-08-15 | 2020-08-14 | Multispecific antigen-binding molecules for cell targeting and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022001942A true MX2022001942A (es) | 2022-07-27 |
Family
ID=72243251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022001942A MX2022001942A (es) | 2019-08-15 | 2020-08-14 | Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas. |
Country Status (12)
Country | Link |
---|---|
US (3) | US20210047438A1 (es) |
EP (1) | EP4013797A1 (es) |
JP (1) | JP2022545647A (es) |
KR (1) | KR20220044821A (es) |
CN (1) | CN114302893A (es) |
AU (1) | AU2020330063A1 (es) |
BR (1) | BR112022002012A2 (es) |
CA (1) | CA3147791A1 (es) |
IL (1) | IL290299A (es) |
MX (1) | MX2022001942A (es) |
TW (1) | TW202120553A (es) |
WO (1) | WO2021030680A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116710124A (zh) | 2020-12-17 | 2023-09-05 | 瑞泽恩制药公司 | 包封蛋白质的微凝胶的制造 |
EP4281542A1 (en) | 2021-01-20 | 2023-11-29 | Regeneron Pharmaceuticals, Inc. | Methods of improving protein titer in cell culture |
BR112023023067A2 (pt) * | 2021-05-04 | 2024-01-30 | Regeneron Pharma | Receptores de antigénios quiméricos com especificidade mage-a4 e usos dos mesmos |
WO2023006809A1 (en) * | 2021-07-27 | 2023-02-02 | Morphosys Ag | Combinations of antigen binding molecules |
WO2023183758A2 (en) * | 2022-03-19 | 2023-09-28 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules targeting cd3 and mage-a4 and uses thereof |
WO2024028386A1 (en) * | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991003493A1 (en) * | 1989-08-29 | 1991-03-21 | The University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
US7550143B2 (en) * | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
JP5011277B2 (ja) * | 2005-04-06 | 2012-08-29 | アイビーシー・ファーマシューティカルズ・インコーポレーテッド | ホモダイマー、ホモテトラマーまたはダイマーのダイマーのからなる安定に連結された複合体を発生させるための方法および使用 |
KR101747103B1 (ko) | 2009-06-26 | 2017-06-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
HUE029785T2 (en) | 2010-02-08 | 2017-04-28 | Regeneron Pharma | Common mouse light chain |
US20150203591A1 (en) * | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
JP2014124186A (ja) * | 2012-12-26 | 2014-07-07 | Industrial Technology Research Institute | 多価抗体フラグメントおよびその三量体化複合体 |
TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
JP6773679B2 (ja) | 2015-03-30 | 2020-10-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Fcガンマ受容体に対する結合が低下した重鎖定常領域 |
TWI784917B (zh) | 2015-09-23 | 2022-11-21 | 美商再生元醫藥公司 | 最優化抗cd3雙特異性抗體及其用途 |
LT3515946T (lt) * | 2016-09-23 | 2022-08-10 | Regeneron Pharmaceuticals, Inc. | Anti-muc16 (mucin 16) antikūnai |
WO2018178074A1 (en) * | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Trimeric antigen binding molecules specific for a costimulatory tnf receptor |
-
2020
- 2020-08-14 CN CN202080061412.XA patent/CN114302893A/zh active Pending
- 2020-08-14 WO PCT/US2020/046352 patent/WO2021030680A1/en unknown
- 2020-08-14 BR BR112022002012A patent/BR112022002012A2/pt unknown
- 2020-08-14 AU AU2020330063A patent/AU2020330063A1/en active Pending
- 2020-08-14 EP EP20761991.7A patent/EP4013797A1/en active Pending
- 2020-08-14 MX MX2022001942A patent/MX2022001942A/es unknown
- 2020-08-14 CA CA3147791A patent/CA3147791A1/en active Pending
- 2020-08-14 JP JP2022509082A patent/JP2022545647A/ja active Pending
- 2020-08-14 KR KR1020227008242A patent/KR20220044821A/ko unknown
- 2020-08-14 TW TW109127674A patent/TW202120553A/zh unknown
- 2020-08-14 US US16/993,721 patent/US20210047438A1/en active Pending
-
2022
- 2022-02-02 IL IL290299A patent/IL290299A/en unknown
- 2022-04-08 US US17/716,830 patent/US20220251244A1/en active Pending
- 2022-10-17 US US17/967,418 patent/US11952430B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20220251244A1 (en) | 2022-08-11 |
KR20220044821A (ko) | 2022-04-11 |
EP4013797A1 (en) | 2022-06-22 |
IL290299A (en) | 2022-04-01 |
WO2021030680A1 (en) | 2021-02-18 |
JP2022545647A (ja) | 2022-10-28 |
AU2020330063A1 (en) | 2022-03-24 |
CA3147791A1 (en) | 2021-02-18 |
US20210047438A1 (en) | 2021-02-18 |
CN114302893A (zh) | 2022-04-08 |
BR112022002012A2 (pt) | 2022-06-07 |
US20230068129A1 (en) | 2023-03-02 |
TW202120553A (zh) | 2021-06-01 |
US11952430B2 (en) | 2024-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022001942A (es) | Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas. | |
AU2018318303A1 (en) | Antigen-binding proteins targeting shared antigens | |
PH12016501384B1 (en) | Human antibodies to pd-l1 | |
WO2021097365A3 (en) | Antigen-binding proteins targeting shared neoantigens | |
MX2022014463A (es) | Construcciones de union a antigeno para moleculas diana. | |
ZA201804654B (en) | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates | |
PH12015502278A1 (en) | Novel bispecific binding molecules with antitumoral activity | |
MX2019008146A (es) | Virus alterado. | |
EP4257611A3 (en) | Anti-muc1 antibody | |
AU2012222463A8 (en) | Cea antibodies | |
MY196874A (en) | Humanized anti-basigin antibodies and the use thereof | |
MX2021008216A (es) | Anticuerpos anti-tigit. | |
MX2022010471A (es) | Anticuerpos monoclonales especificos para el antigeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por vrsh. | |
PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof | |
MX2021014966A (es) | Anticuerpos anti-cd3 dependientes de ph modificados geneticamente y metodos para su generacion y uso. | |
WO2020123662A3 (en) | Fusion protein constructs for complement associated disease | |
MX2021009275A (es) | Moleculas de union especificas. | |
MX2022001032A (es) | Agentes terapeuticos multiespecificos a base en aptameros. | |
ZA202205288B (en) | Humanized antibody and method for using the same | |
WO2015191590A3 (en) | Combination therapies targeting tumor-associated stroma or tumor cells and microtubules | |
MX2022000379A (es) | Anticuerpos que se unen a celulas cancerosas yque dirigen radionucleidos a dichas celulas. | |
MX2022007116A (es) | Anticuerpo anti-c5 para el tratamiento del trastorno del espectro de la neuromielitis optica. | |
WO2015191583A3 (en) | Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase | |
MX2022001882A (es) | Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40. | |
MX2023007028A (es) | Composiciones de proteínas y métodos para producir y usar las mismas. |